P261 Temporal variations of aspirin resistance in patients with acute coronary syndrome

✍ Scribed by M. Tsekoura; T. Papaioannou; M. Vavuranakis; Z. Palantza; G. Rossos; C. Stefanadis; E. Bossinakou

• Book ID: 104323115
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 79 KB
• Volume: 21
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(07)70138-8

✦ Synopsis

Resistance to aspirin and clopidogrel is implicated in the occurrence of recurrent ischemia in patients (pts) with acute coronary syndrome (ACS), although non-compliance has also been linked to the occurrence of the events. We investigated whether aspirin and clopidogrel platelet inhibition are different after documented administration of dual antiplatelet therapy for one week. Methods: Twenty-two patients with ACS (16 males, 6 females) were investigated. All patients received clopidogrel 75 mg daily and aspirin 160 mg daily for 1 week. PFA was used to estimate resistance to aspirin and clopidogrel after 1 week of treatment. PFA-100 results were considered abnormal when the occlusion time was higher than 193 s for PFA-EPI and 120 s for PFA-ADP. Results: After 1 week of treatment in patients receiving aspirin, 11 out of 22 (50%) showed aspirin resistance, while in patients receiving clopidogrel 19 out of 22 (86%) had resistance, (p = 0.02). Conclusion: Resistance to aspirin and clopidogrel occurs despite adequate compliance with medication. Administration of 75 mg of clopidogrel daily results in a significantly higher percentage of resistance in platelets than 160 mg of aspirin.